The synthetic varespladib molecule is a multi-functional inhibitor for PLA2 and PLA2-like ophidic toxins

• Published in: Biochimica et biophysica acta. General subjects 2021-07, Vol.1865 (7), p.129913-129913, Article 129913
• Main Authors: Salvador, Guilherme H.M., Borges, Rafael J., Lomonte, Bruno, Lewin, Matthew R., Fontes, Marcos R.M.
• Format: Article
• Language: English
• Subjects: Lys49-phospholipases A2 proteins; Myotoxicity inhibition; Phospholipase A2 - like proteins; Phospholipase A2 inhibitor; Snake venom; Varespladib inhibitor
• ISSN: 0304-4165; 1872-8006
• DOI: 10.1016/j.bbagen.2021.129913

The treatment for snakebites is early administration of antivenom, which can be highly effective in inhibiting the systemic effects of snake venoms, but is less effective in the treatment of extra-circulatory and local effects. To complement standard-of-care treatments such as antibody-based antivenoms, natural and synthetic small molecules have been proposed for the inhibition of key venom components such as phospholipase A2 (PLA2) and PLA2-like toxins. Varespladib (compound LY315920) is a synthetic molecule developed and clinically tested aiming to block inflammatory cascades of several diseases associated with high PLA2s. Recent studies have demonstrated this molecule is able to potently inhibit snake venom catalytic PLA2 and PLA2-like toxins. In vivo and in vitro techniques were used to evaluate the inhibitory effect of varespladib against MjTX-I. X-ray crystallography was used to reveal details of the interaction between these molecules. A new methodology that combines crystallography, mass spectroscopy and phylogenetic data was used to review its primary sequence. Varespladib was able to inhibit the myotoxic and cytotoxic effects of MjTX-I. Structural analysis revealed a particular inhibitory mechanism of MjTX-I when compared to other PLA2-like myotoxin, presenting an oligomeric-independent function. Results suggest the effectiveness of varespladib for the inhibition of MjTX-I, in similarity with other PLA2 and PLA2-like toxins. Varespladib appears to be a promissory molecule in the treatment of local effects led by PLA2 and PLA2-like toxins (oligomeric dependent and independent), indicating that this is a multifunctional or broadly specific inhibitor for different toxins within this superfamily. •Varespladib is able to inhibit both cytotoxic and myotoxic activities of MjTX-I.•Varespladib binds to putative MDoS from MjTX-I being responsible for its inhibition.•Different of other PLA2-like toxins, MjTX-I has an oligomeric-independent activity.•Varespladib behaves as class 2 inhibitor for MjTX-I.•MjTX-I is evolutionary positioned between catalytic PLA2s and PLA2-like toxins.